BioCardia公司近日宣布，其Helix经心内膜输送导管的预提交批准方案已获得美国食品药品监督管理局（FDA）的正式受理。这一进展标志着该创新医疗器械在监管审批流程中迈出关键一步。
BioCardia公司近日宣布，其Helix经心内膜输送导管的预提交批准方案已获得美国食品药品监督管理局（FDA）的正式受理。这一进展标志着该创新医疗器械在监管审批流程中迈出关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.